UTSW at 2026 ASCO Annual Meeting

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, faculty and researchers from UT Southwestern Harold C. Simmons Comprehensive Cancer Center are presenting leading-edge research and clinical advancements that are helping shape the future of cancer care.

This year’s presentations highlight progress across a wide range of disease sites and specialties, including translational research, precision oncology, innovative therapeutics, clinical trials, survivorship, and patient-centered care. We invite you to explore the presentations below to learn more about the work our teams are advancing to improve outcomes for patients locally and around the world. 

Oral Presentations
Date	Time	Session Topic	Poster Title	Speaker
May 30	8:00-9:30	Clinical Science Symposium: New Approaches to Curing Bladder and Kidney Cancer	Panel Questions and Answers	Co-Chair: Qian Qin, M.D.
	1:15-1:30	Education Session: Integrating Systemic Therapy in Early- and Intermediate-Stage Hepatocellular Carcinoma	Surgeon's Perspective: Is There a Role for Immunotherapy in Adjuvant/Neoadjuvant Hepatocellular Carcinoma Management?	Adam Yopp, M.D.
	2:00-2:30		Panel Questions and Answers	Moderator: Adam Yopp, M.D.
	5:00-5:15	Triple-Negative Breast Cancer in 2026: Translating New Data Into Clinical Decisions	Personalizing Curative Therapy in Stage 2-3 Triple-Negative Breast Cancer	Heather McArthur, M.D., M.P.H., FASCO
	5:30-6:00		Panel Questions and Answers	Heather McArthur, M.D., M.P.H., FASCO
May 31	8:00-8:15	Highlights of the Year I	Highlights in Genitourinary Cancer: Antibody-Drug Conjugates Transforming Bladder Cancer	Tian Zhang, M.D.
June 1	2:15-2:21	Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary	Tegavivint, a downstream Wnt/B=catenin inhibitor: Dose-finding results from a phase 1/2 trail in advanced hepatocellular carcinoma	David Hsieh, M.D.
	2:33-2:45		Panel Questions and Answers	Moderator: David Hsieh, M.D.
Poster Presentations
Date	Time	Session Topic	Poster Title	Speaker
May 30	9:00-12:00	Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary	Precalence of CDH1 germline variants in gastric cancer patients with exome-inferred ancestry	Skylar Nahi, M.D.
		Care Delivery/Models of Care	Lost in translation? Evaluating associations between English proficiency and next generation sequencing completion, and comparing understandability across different translation modalitlies among Spanish speakers with metastatic breast cancer.	Daniela Tovar
	1:30-4:30	Developmental Therapeutics—Immunotherapy	Association of mRNA COVID-19 vaccination near immune checkpoint inhibitor initiation with outcomes: A real-world analysis.	Changchuan "Charles" Jiang, M.D., M.P.H.
			Association of mRNA COVID-19 vaccination near immune checkpoint inhibitor initiation with outcomes: A real-world analysis.	Changchuan "Charles" Jiang, M.D., M.P.H.
		Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	A phase 2 multi-center pharmacodynamics study of the fatty acid synthase (FASN) inhibitor TVB-2640 in advanced KRAS-mutant non-small cell lung cancer.	Arthi Sridhar, M.D.
May 31	9:00-12:00	Genitourinary Cancer—Kidney and Bladder	Clinical outcomes for patients (pts) with synchronous versus metachronous metastatic urothelial cancer (mUC) treated with enfortumab vedotin and pembrolizumab (EV-P).	Libin Yan, MD, Ph.D.
			Proteomic profiling of circulating tumor cells (CTCs) in metastatic urothelial cancer (mUC) as associated with upregulation of EGFR, HER2, and B7-H3 in patients (pts) progressing on enfortumab vedotin (EV) plus pembrolizumab.	Wadih Issa,  M.D.
			A phase II trial of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or surgically challenging clear cell renal cell carcinoma (EXPLORE-RCC).	Qian Qin, M.D.
			Advancing treatment of low-grade upper tract urothelial carcinoma (LG UTUC) with padeliporfin vascular-targeted photodynamic therapy (VTP): The ENLIGHTED phase 3 trial.	Vitaly Margulis, M.D.
June 1	9:00-12:00	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	Late infectious complications after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphomas (LCBL): Real-world predictors and outcomes.	Daniel Goyco Vera, M.D.
		Quality Care/Health Services Research	Safety-net coverage instability during cancer care and association with overall survival.	Liyang Yuan, M.S.
			Trends in ivermectin medication records with cancer as the primary diagnosis following public attention: A national EHR analysis.	Changchuan "Charles" Jiang, M.D., M.P.H.
	1:30-4:30	Breast Cancer - Local/Regional/Adjuvant	Event-free survival from the randomized phase 2 neoHIP trial evaluating neoadjuvant taxane, HER2-targeted therapy, +/- pembrolizumab in early-stage HER2-positive breast cancer.	Heather McArthur, M.D., M.P.H., FASCO
		Prevention, Risk Reduction, and Genetics	Variants of uncertain significance and contralateral risk-reducing mastectomy in early-stage breast cancer across safety-net and private hospital settings.	Vineeth Reddy Kommidi, M.D.
		Pediatric Oncology	Changes in the incidence of second malignant neoplasms in neuroblastoma over time: An updated SEER database analysis.	Arhanti Sadanand, M.D.